Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.

Yuxin MuXuezhi HaoPuyuan XingXingsheng HuYan WangTeng LiJinyao ZhangZiyi XuJun-Ling Li

Published in: Journal of cancer research and clinical oncology (2020)

The study revealed heterogeneous mechanisms of resistance to osimertinib in advanced NSCLC patients and their association with clinical outcomes. Patients who maintained T790M mutation or with EGFR-dependent resistance mechanism had longer clinical outcome benefits.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
brain metastases
tyrosine kinase
single cell
patient reported outcomes
patient reported